Day: December 31, 2020

Press Release31 December 2020Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the treatment of Hepatocellular Carcinoma (HCC). The designation was based on data from a Phase I/II clinical trial of ilixadencel in patients with unresectable and/or metastatic HCC. The Orphan Drug Act was enacted in the United States to support the development of new drugs and biologics for rare diseases through financial incentives, such as partial tax credit for clinical trial costs, and up to seven years of market exclusivity upon regulatory product...

Pressmeddelande31 december 2020Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av levercancerImmunicum AB (publ; IMMU.ST) tillkännager idag att bolaget har erhållit särläkemedelsstatus (Orphan Drug Designation, ODD) från den amerikanska läkemedelsmyndigheten, FDA, för bolagets ledande kandidat ilixadencel, en cellbaserad och lagringsbar immunaktiverare, för behandling av levercancer (HCC). FDA:s beslut grundar sig på resultaten från en klinisk fas I/II-studie av ilixadencel hos patienter med tumörer som inte går att avlägsna kirurgiskt och/eller spridd (metastaserad) levercancer (HCC). Den så kallade Orphan Drug Act-lagen antogs i USA för att stödja utvecklingen av nya läkemedel och biologiska terapier för sällsynta sjukdomar genom finansiella incitament, såsom avdragsmöjligheter för studiekostnader...

MINNEAPOLIS, Dec. 31, 2020 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC) today announced that it expects to release its fiscal 2021 first quarter financial results on Thursday, January 7, 2021, before the market opens. A copy of the news release will be available on the Investor Relations section of NTIC’s webpage (www.ntic.com).In conjunction with NTIC’s release of its financial and operating results, investors, analysts and other interested parties are invited to participate in a conference call with management on Thursday, January 7, 2021, at 9:00 a.m. Eastern Time.Patrick Lynch, President and CEO, and Matt Wolsfeld, CFO will review NTIC’s fiscal 2021 first quarter financial results and outlook, which will be followed by a question and answer session.Details for the conference call are as follows.CONFERENCE...

LOS ANGELES, Dec. 31, 2020 (GLOBE NEWSWIRE) — via InvestorWire — Tongji Healthcare Group, Inc. (OTCMKTS:TONJ) (name change to “Clubhouse Media Group, Inc.” currently pending) (“Tongji,” “Clubhouse Media Group,” “Clubhouse” or the “Company”) is pleased to take a look back at an exciting year featuring a number of branding deals with high-profile client brands.“We can’t disclose our biggest clients quite yet, though we hope to in the very near future,” commented Amir Ben-Yohanan, CEO of Clubhouse Media Group. “Nonetheless, we have established a branding footprint that has drawn some of the most sought-after names in the fashion, luxury goods, and consumer products markets in the world. We have built a formidable global branding machine at Clubhouse, and we have big plans to mobilize and monetize it further in 2021.”Over recent...

NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) — DarkPulse, Inc. (OTC Markets: DPLS) (“DarkPulse” or the “Company”), a technology-security company focused on the manufacture, sale, installation and monitoring of laser sensing systems based on its patented BOTDA dark-pulse sensor technology (the “DarkPulse Technology”) which provides a data stream of critical metrics for assessing the health and security of infrastructure for applications in border security, railroad, oil and gas, aviation and aerospace, and mine safety, today announced it has appointed Mr. Faisal Farooqui as its Director for Asia-Pacific (“APAC”) and Middle East and North Africa (“MENA”) global regions. Mr. Farooqui will establish sales operations for MENA and APAC regions. He is responsible for establishing India & Dubai offices for the company while tasked with...

VANCOUVER, British Columbia, Dec. 31, 2020 (GLOBE NEWSWIRE) — Hunter Technology Corp. (TSX-V: HOC; OTCQB: HOILF; WKN: A2QEYH, FSE: RWPM, ISIN: CA4457371090) (“Hunter” or the “Company”) is pleased to announce that it has closed the acquisition of FinFabrik Limited (“FinFabrik”).Hunter has acquired 100% of the issued and outstanding shares of FinFabrik in exchange for 12,110,203 common shares of Hunter (the “Shares”) at a deemed price of USD $0.90 per Share and the payment of USD $250,000 in cash, for total consideration of USD $11,149,182. The Shares issued to the former shareholders of FinFabrik are subject to statutory holds periods as well as a contractual hold period of up to one year. For additional information regarding FinFabrik or the transaction, please see Hunter’s news release dated December 14, 2020, which is available...

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).“We are pleased to commence dosing in our second proof-of-concept study of LX9211,” said Praveen Tyle, Ph.D., executive vice president of research and development. “People who develop shingles often suffer with persistent pain for months to years after the rash clears with limited treatment options. We believe LX9211 has the potential to offer a novel therapeutic approach to treating post-herpetic neuralgia. We look forward to completing this study and our...

VANCOUVER, British Columbia, Dec. 31, 2020 (GLOBE NEWSWIRE) — Hunter Technology Corp. (TSX-V: HOC; OTCQB: HOILF; WKN: A2QEYH, FSE: RWPM, ISIN: CA4457371090) (“Hunter” or the “Company”) is pleased to announce that it has closed the acquisition of FinFabrik Limited (“FinFabrik”).Hunter has acquired 100% of the issued and outstanding shares of FinFabrik in exchange for 12,110,203 common shares of Hunter (the “Shares”) at a deemed price of USD $0.90 per Share and the payment of USD $250,000 in cash, for total consideration of USD $11,149,182. The Shares issued to the former shareholders of Finfabrik are subject to statutory holds periods as well as a contractual hold period of up to one year. For additional information regarding FinFabrik or the transaction, please see Hunter’s news release dated December 14, 2020, which is available...

SELSKABSMEDDELELSEDato: 31. december 2020Selskabsmeddelelse nr.: 16Blue Vision A/S – Godkendt årsrapportVedhæftet er årsrapporten for 2019 som blev godkendt på selskabets ordinære generalforsamling tidligere i dag.Blue Vision A/SBestyrelsenVedhæftet filBlue Vision Årsrapport 2019 – godkendt af generalforsamling3112020

TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) — EEStor Corporation (TSX.V: ESU) (“EEStor” or the “Corporation”) is pleased to provide the following update on certain ongoing corporate transactions:Update on Acquisition of GreenNH3The licensing and acquisition of GreenNH3 patented technology continues to progress, and technical due diligence for this stage has now been completed. The Corporation expects to finalize definitive documentation for the transaction shortly, following which regulatory approval will be sought.Private PlacementThe Corporation intends to complete an offering (the “Offering”) of 400,000 units (each, a “Unit”) by way of non-brokered private placement. The Units will be offered at a price of $0.05 per Unit for gross proceeds of $20,000. Each “Unit” will consist of one common share of the Corporation, and one share...